Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial
Nutrients · 01.10.2024 · 16 (19) · 3333
DOI: 10.3390/nu16193333 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Nutrients, online erschienen am 01.10.2024. Verfasst von Nozomi Matsuura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Science, Health Science Business Division, Kirin Holdings Company, Limited, Fujisawa, Kanagawa 251-8555, Japan. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Probiotics, Prebiotics, Gastrointestinal Microbiome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kirin Holdings Company, Limited.
Abstract (Originalsprache)
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients.
Methods
Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (−38.0 [95% confidence interval (CI): −53.6, −22.4]; p < 0.001), in patients with IBS-D (−44.5 [95% CI: −70.6, −18.5]; p = 0.004) and IBS-C (−51.2 [95% CI: −79.4, −22.9]; p = 0.002), but not in those with IBS-M (−20.0 [95% CI: −48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention.
Conclusions
In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Health Science, Health Science Business Division, Kirin Holdings Company, Limited, Fujisawa, Kanagawa 251-8555, Japan.
- Soiken Inc., Chiyoda, Tokyo 101-0052, Japan.
- EviPRO Co., Ltd., Chiyoda, Tokyo 101-0032, Japan.
- Thorne HealthTech, Inc., New York, NY 10019, USA.
- Torii Medical Clinic, Setagaya, Tokyo 157-0066, Japan.
Förderung
- Kirin Holdings Company, Limited
Zitieren
APA
Matsuura, N., Kanayama, M., Watanabe, Y., Yamada, H., Lili, L., & Torii, A. (2024). Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial. Nutrients, 16(19), 3333. https://doi.org/10.3390/nu16193333
Vancouver
Matsuura N, Kanayama M, Watanabe Y, Yamada H, Lili L, Torii A. Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial. Nutrients. 2024;16(19):3333. doi:10.3390/nu16193333
BibTeX
@article{Matsuura2024,
author = {Matsuura, Nozomi and Kanayama, Masaya and Watanabe, Yuta and Yamada, Hirokazu and Lili, Loukia and Torii, Akira},
title = {Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial},
journal = {Nutrients},
year = {2024},
volume = {16},
number = {19},
pages = {3333},
doi = {10.3390/nu16193333}
}
EUVIMED